Shots: The P-III MONALEESA-3 study involves assessing of Kisqali (ribociclib) + fulvestrant in postmenopausal women with HR+/HER2- advanced or m-breast cancer The second phase of P-III MONALEESA-3 study resulted in meeting […]readmore
Tags : Phase
Shots: Alnylam to add an additional investigational product through the end of IND-enabling studies in Sanofi’s subsidiary Genzyme and Alnylam in 2014 deal, where companies collaborated to develop and commercialize […]readmore